SALT
LAKE CITY (June 25, 2019) – Predictive
Laboratories, a wholly owned subsidiary of Predictive Technology Group, Inc.
(OTC PINK: PRED), a leader in the use of data analytics for disease
identification and subsequent clinical intervention through precision
therapeutic treatments, announces that data from a study of the genes
underlying endometriosis may lead to new pathophysiology insights, improved
diagnostics and novel treatment approaches. The study data was discussed in an
oral presentation by Kenneth Ward, M.D. at the 2019 European Society of Human
Reproduction and Embryology (ESHRE) annual meeting in Vienna, Austria.
The abstract of
the presentation “Excess germline mutations in four genes in
unrelated women with surgical endometriosis” is available at https://www.eshre.eu/ESHRE2019/Programme/Searchable#!abstractdetails/0000581010.
“Predictive Laboratories is
committed to comprehensive disease management and advancing research into the
genetic cause of endometriosis to improve the diagnosis and management of
patients suffering from the disease,” said Bradley Robinson, CEO of Predictive Technology Group. “Our investment in technology has led to the
identification of additional germline DNA changes associated with
endometriosis.”
The study was conducted to identify genes in patients
with endometriosis versus the general population. Whole exome sequencing was used
to identify four genes (ZNF586, LUZP4, POP4 and UNC5CL) with significant gene
burden in over 2,500 women with endometriosis, which was significant
versus the general population (p<5 x 10-8). The four newly discovered mutated genes are all involved in the
regulation of gene expression. Importantly, it was found that one
in four women with endometriosis carry a mutation in one of these genes, while
the population frequency is only 8%.
“Our research may lead to a
better understanding of the pathophysiology of
endometriosis,” said Dr. Ward, CEO of Juneau Biosciences, Laboratory Director
of Predictive Laboratories and a member of the Predictive Technology Group
Scientific Advisory Board. “Given the pace of innovation for targeted therapy,
we are thrilled to present clinically relevant insights that may result in
improved treatment of infertility as a result of endometriosis.”
About Endometriosis
Endometriosis occurs when the
endometrial tissue that lines the uterus grows outside of the uterus and onto
other areas of the body. Symptoms include pelvic pain, heavy periods, pain
during sexual intercourse or bowel movements and infertility. Endometriosis
affects 1 in 10 women worldwide in the reproductive age group. This prevalence
increases to 1 in 3 women with infertility and 1 in 2 women with a normal cycle
whose partner has normal sperm.
About
ESHRE
The
European Society of Human Reproduction and Embryology (ESHRE) is an
international non-profit organization of about 8,000 members, whose main
objective is to promote the study of human reproduction. ESHRE organizes the
world’s major event in reproduction each year, publishes leading journals and
guidelines, organizes lifelong learning programs and certification schemes, and
monitors European IVF data.
Selection
of the abstract for publication in the press program does not imply endorsement
by ESHRE of the products and/or services that Predictive Laboratories offers.
About Predictive Laboratories, Inc.
Predictive Laboratories owns significant next-generation
sequencing and genotyping assets along with extensive protocols, quality and
laboratory management systems and other resources required by a “high
complexity” molecular diagnostic laboratory operating under the Clinical
Laboratory Improvement Act (CLIA). The group recently launched its novel test
for women experiencing infertility, called ARTGuide™, to selected Beta launch
centers. ARTGuide™ is a proprietary gene test panel for women experiencing
infertility as a result of endometriosis and other health concerns, in 2018.
The test is expected to change the way that Advanced Reproductive Technologies
(ART), such as in vitro fertilization (IVF), are used to assist couples having
difficulty conceiving a pregnancy.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to
revolutionize patient care through predictive data analytics, novel gene-based
diagnostics and companion therapeutics through its subsidiaries Predictive
Therapeutics, Predictive Biotech, and Predictive Laboratories. These
subsidiaries are focused on endometriosis, scoliosis, degenerative disc
disease, and human cell and tissue products. The subsidiaries use genetic and
other information as cornerstones in the development of new diagnostics that
assess a person’s risk of illness and therapeutic products designed to
identify, prevent and treat diseases more effectively. Additional information
is available at Predtechgroup.com, Predrx.com, Predictivebiotech.com,
and Predictivelabs.com.
Forward-Looking Statements
To the extent any statements
made in this release contain information that is not historical, these
statements are essentially forward-looking and are subject to risks and
uncertainties, including the difficulty of predicting FDA approvals, acceptance
and demand for human cell and tissue products and other pharmaceutical
products, the impact of competitive products and pricing, new product
development and launch, reliance on key strategic alliances, availability of
raw materials, availability of additional intellectual property rights,
availability of future financing sources, the regulatory environment, and other
risks the Company may identify from time to time in the future.
Predictive Technology Group announces its 11th Consecutive Quarter of Revenue Growth
/in Predictive Technology Group, Press Releases /by Yes InternationalAffirms business strategy and milestones
SALT LAKE CITY (July 15, 2019) – Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapeutic treatments, announces the continuation of consecutive quarter revenue growth for the fiscal 2019 fourth quarter ended June 30, 2019.
“We are proud of our revenue growth, fundamentals and business momentum. We continue to make excellent progress with our strategy to increase sales from our human cell and tissue products, while preparing for the full commercial launch in the coming quarters of our genetic-based endometriosis and fertility diagnostic/prognostic tests,” said Bradley Robinson, CEO of Predictive Technology Group.
“Over the past several months we made significant strides in building a strong infrastructure,” Robinson added. “We strengthened our executive leadership and our board of directors, announced a key global collaboration with Thermo Fisher Scientific to better understand the genetic factors underlying infertility, and presented new genetic data at key industry conferences. We also completed the integration of two DNA laboratories into Predictive Laboratories at a much faster pace than anticipated, and appointed experienced industry veterans to lead this state-of-the-art facility. Additionally, we filed a Form 10 with the United States Securities and Exchange Commission (US SEC) that is effective, making Predictive Technology Group a full reporting 1934 Exchange Act compliant company. And, we submitted an application, which is currently under review, to list Predictive Technology Group’s common stock for trading on The NASDAQ Stock Market.”
The Company expects to report its fourth quarter and fiscal 2019 full year financial results in September 2019.
Predictive is aware that a short-seller recently issued a critical opinion piece regarding the Company in an attempt to manipulate the Company’s stock price. “This opinion piece was produced by anonymous author(s) who admit in the opinion piece that they ‘have taken a really large short position in shares’ of our Company and ‘stand to benefit financially if the stock price declines,’” said John Sorrentino, Chairman of Predictive Technology Group. “As stated in the short-seller opinion’s disclaimers, the anonymous authors refuse to stand behind their allegations – they make ‘no representation, express or implied, as to the accuracy, timeliness, or completeness of [the opinion’s] information. . .’ Given that the short-seller opinion is intended to drive down the price of the Company’s stock and the opinion’s authors have refused to guarantee the accuracy of the ‘information’ the opinion espouses, the Company will not dignify the opinion piece with a point-by-point response. The Company remains focused on developing products that have the potential to improve the quality of life for people throughout the world.”
The Company notes, however, that some of the topics raised in the piece – including the Company’s recent acquisitions – are fully disclosed, in detail, in the Company’s filings with the US SEC. The Company encourages stakeholders to review the detail of these transactions in its US SEC Edgar filings.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com, Predrx.com, Predictivebiotech.com, and Predictivelabs.com.
Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
Contact:
For more information, visit www.predtechgroup.com
ELEMENT GLOBAL, INC. (ELGL) ANNOUNCES A “LETTER OF INTENT” ON ACQUIRING ELEMENT INTERNATIONAL GROUP
/in Element Global, Inc., Press Releases /by Yes InternationalVirginia Beach, VA- July 9, 2019- Element Global, Inc. (OTC:ELGL) announces that its management team signed a “Letter of Intent” to acquire the assets of Element International Group.
Element International Group contains a number of assets in the mining, media, energy, and technologies sectors.
Upon successfully completing due diligences, ELGL’s and Element International Group’s management believes they can move forward with the acquisition details. Once finalized, expect a new board of directors and officers appointments to be announced at ELGL.
As more information becomes available, ELGL plans to update, accordingly.
For further information about this release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, at 757-306-6090, yes@yesinternational.com and www.yesinternational.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.
PREDICTIVE TECHNOLOGY GROUP ANNOUNCES THE PRESENTATION OF NEW DATA DEMONSTRATING THE GENETIC BASIS OF ENDOMETRIOSIS AT ESHRE
/in Uncategorized /by Yes InternationalSALT LAKE CITY (June 25, 2019) – Predictive Laboratories, a wholly owned subsidiary of Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapeutic treatments, announces that data from a study of the genes underlying endometriosis may lead to new pathophysiology insights, improved diagnostics and novel treatment approaches. The study data was discussed in an oral presentation by Kenneth Ward, M.D. at the 2019 European Society of Human Reproduction and Embryology (ESHRE) annual meeting in Vienna, Austria.
The abstract of the presentation “Excess germline mutations in four genes in unrelated women with surgical endometriosis” is available at https://www.eshre.eu/ESHRE2019/Programme/Searchable#!abstractdetails/0000581010.
“Predictive Laboratories is committed to comprehensive disease management and advancing research into the genetic cause of endometriosis to improve the diagnosis and management of patients suffering from the disease,” said Bradley Robinson, CEO of Predictive Technology Group. “Our investment in technology has led to the identification of additional germline DNA changes associated with endometriosis.”
The study was conducted to identify genes in patients with endometriosis versus the general population. Whole exome sequencing was used to identify four genes (ZNF586, LUZP4, POP4 and UNC5CL) with significant gene burden in over 2,500 women with endometriosis, which was significant versus the general population (p<5 x 10-8). The four newly discovered mutated genes are all involved in the regulation of gene expression. Importantly, it was found that one in four women with endometriosis carry a mutation in one of these genes, while the population frequency is only 8%.
“Our research may lead to a better understanding of the pathophysiology of endometriosis,” said Dr. Ward, CEO of Juneau Biosciences, Laboratory Director of Predictive Laboratories and a member of the Predictive Technology Group Scientific Advisory Board. “Given the pace of innovation for targeted therapy, we are thrilled to present clinically relevant insights that may result in improved treatment of infertility as a result of endometriosis.”
About Endometriosis
Endometriosis occurs when the endometrial tissue that lines the uterus grows outside of the uterus and onto other areas of the body. Symptoms include pelvic pain, heavy periods, pain during sexual intercourse or bowel movements and infertility. Endometriosis affects 1 in 10 women worldwide in the reproductive age group. This prevalence increases to 1 in 3 women with infertility and 1 in 2 women with a normal cycle whose partner has normal sperm.
About ESHRE
The European Society of Human Reproduction and Embryology (ESHRE) is an international non-profit organization of about 8,000 members, whose main objective is to promote the study of human reproduction. ESHRE organizes the world’s major event in reproduction each year, publishes leading journals and guidelines, organizes lifelong learning programs and certification schemes, and monitors European IVF data.
Selection of the abstract for publication in the press program does not imply endorsement by ESHRE of the products and/or services that Predictive Laboratories offers.
About Predictive Laboratories, Inc.
Predictive Laboratories owns significant next-generation sequencing and genotyping assets along with extensive protocols, quality and laboratory management systems and other resources required by a “high complexity” molecular diagnostic laboratory operating under the Clinical Laboratory Improvement Act (CLIA). The group recently launched its novel test for women experiencing infertility, called ARTGuide™, to selected Beta launch centers. ARTGuide™ is a proprietary gene test panel for women experiencing infertility as a result of endometriosis and other health concerns, in 2018. The test is expected to change the way that Advanced Reproductive Technologies (ART), such as in vitro fertilization (IVF), are used to assist couples having difficulty conceiving a pregnancy.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com, Predrx.com, Predictivebiotech.com, and Predictivelabs.com.
Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
PREDICTIVE TECHNOLOGY GROUP ANNOUNCES THE PRESENTATION OF NEW GENETIC FINDINGS IN ENDOMETRIOSIS AT THE 35TH ANNUAL MEETING OF THE EUROPEAN SOCIETY OF HUMAN REPRODUCTION AND EMBRYOLOGY
/in Predictive Technology Group, Press Releases /by Yes InternationalSALT LAKE CITY (June 20, 2019) – Predictive Laboratories, a wholly owned subsidiary of Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapeutic treatments, announces that Kenneth Ward, M.D. will present new genetic findings in endometriosis at the 2019 European Society of Human Reproduction and Embryology (ESHRE) meeting on Monday, June 24 in Vienna, Austria.
Dr. Ward is CEO of Juneau Biosciences, Laboratory Director of Predictive Laboratories and a member of the Predictive Technology Group Scientific Advisory Board. Predictive Technology Group inlicensed the technology supporting its ARTGuide® Test for endometriosis and other genetic causes of infertility from Juneau Biosciences and is Juneau Biosciences’ largest shareholder.
“Predictive is committed to understanding the biology, diagnosis and treatment of endometriosis,” said Bradley Robinson, President and CEO of Predictive Technology Group. “We are thrilled to contribute to the scientific understanding of a disease that has been difficult to treat and believe our investigative efforts will lead to improved patient outcomes in the future.”
Details on the presentation at ESRHE 2019 are as follows:
Abstract Title: Excess Germline Mutations in Four Genes in Unrelated Women with Surgical Endometriosis
Presenting Author: Dr. Kenneth Ward
Presentation Details: Monday, June 24 at 15:30 CEST
Session 23
Room: Strauss 1+2
A press release summarizing the presented data will be issued following the presentation at ESHRE.
About ESHRE
The European Society of Human Reproduction and Embryology (ESHRE) is an international non-profit organization of about 8,000 members, whose main objective is to promote the study of human reproduction. ESHRE organizes the world’s major event in reproduction each year, publishes leading journals and guidelines, organizes lifelong learning programs and certification schemes, and monitors European IVF data.
Selection of the abstract for publication in the press program does not imply endorsement by ESHRE of the products and/or services that Predictive Laboratories offers.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com, Predrx.com, Predictivebiotech.com, and Predictivelabs.com.
Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
Contact:
For more information, visit www.predtechgroup.com
NORTHSTAR’S (NEIK) STRATEGIC PLAN FOR ENTERING THE WORLDWIDE AVIATION MANUFACTURE AND SALES ARENA, WITH PROJECTED ANNUAL REVENUE TO TOP USD34 MILLION
/in Northstar Electronics, Press Releases /by Yes InternationalVirginia Beach, VA, June 19, 2019- Northstar Electronics Inc. (“Northstar,” the “Company”) (OTCQB: NEIK)
Northstar is pleased to announce that it has signed an agreement with a global leader in the aerospace industry, to enable a cashless acquisition of worldwide rights for a family of single engine Turbo-Prop industrial aircraft. Northstar is now working with that company to secure the approval of this agreement for credit under international industrial offset commitments, and to make contractual arrangements for key technical support services as we prepare for production.
To bring our new aircraft to market, Northstar is planning an international expansion through strategic regions and a comprehensive approach to manufacturing, sales, and support. The Company’s primary markets will be Agricultural Aviation, including Crop Seeding and Dusting, as well as Rapid Response Forest Fire-Fighting, all proven markets with increasing global demand. In addition, Northstar plans to leverage its new aircraft design features to become a leader in other emerging markets, such as Cloud Seeding.
With first related revenues as early as 2020, Northstar projects its sales of Aircraft, as well as Aircraft Parts, Support Equipment, and Maintenance, Repair and Overhaul services, to grow to over USD34 Million by 2024, while achieving an EBITDA of 27% of annual revenue.
Northstar CEO Dr. Wilson Russell comments, “This is a special milestone for Northstar in our plans to become a global player in the aviation field. Having secured the IP Rights, we can now focus on working with the overseas company to eventually reach the stage whereby Northstar will be manufacturing the Aircraft.”
For further information about this news release contact, Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, and yes@yesinternational.com.
About Northstar Electronics, Inc.
Northstar Electronics, Inc. (OTCQB:NEIK), established in the late 1990’s, carried out design and manufacturing contracts for various divisions of Lockheed Martin Corporation including LM MS2 (Submarine Command and Control Consoles), LM Canada (Naval Anti-Terrorism System), LM Aeronautics (Parts for P-3 Orion Airplane), and L-3 ( Navy Frigate Command and Control Consoles). Northstar also designed, manufactured, and sold its own sonar-based system to commercial customers. In the past few years, Northstar has moved towards making and selling its own independent systems, www.northstarelectronics.com.
Safe Harbor Statement: This press release may include predictions, estimates, opinions or statements that might be considered “forward-looking” under the provisions of the Private Securities Litigation Reform Act of 1995. Such statements generally can be identified by phrases such as the Company or its management “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates,” or other, similar words or phrases.
Thermo Fisher Scientific and Predictive Laboratories Announce Global Infertility Research Collaboration
/in Predictive Technology Group, Press Releases /by Yes InternationalStudies aim to elucidate infertility genetics for development of noninvasive test to support decision making and improved outcomes for women pursuing fertility treatment
CARLSBAD, Calif., June 19, 2019 /PRNewswire/ — Thermo Fisher Scientific announced today that it has entered into a global research collaboration with Predictive Laboratories, a wholly owned subsidiary of Predictive Technology Group, Inc., (OTC PINK: PRED) focused on studying the genetic factors underlying infertility in women. The work will utilize Thermo Fisher’s various offerings for reproductive health, including Applied Biosystems CarrierScan Assay, Ion ReproSeq PGS Assay, CytoScan Dx Assay, and Ion AmpliSeq Exome RDY for whole exome sequencing.
Infertility has many potential causes, which may involve one or both partners. In some cases, no cause of the condition can be determined, leading the infertility to be described as “unexplained.” The most common causes among women are irregular ovulation, blockage of the fallopian tubes, and endometriosis. The American College of Obstetrics and Gynecology (ACOG) reports that at least 40 percent of women with infertility have endometriosis.
Endometriosis occurs when the endometrial tissue that lines the uterine wall grows in other areas of the body outside of the uterus. While the symptoms are well-characterized, including pelvic pain, heavy periods, and pain during sexual intercourse or bowel movements, the disease is highly variable and many women have asymptomatic endometriosis, which has a significant impact on their fertility. The studies with Predictive Laboratories aim to elucidate the genetic basis of this condition, which is expected to more accurately define which women will experience infertility.
“Infertility among women who seek to conceive has become an increasingly common condition, which leads to much frustration and financial burden as they seek alternative solutions,” said Bradley Robinson, CEO of Predictive Technology Group. “Our collaboration with Thermo Fisher brings together our innovative research and development capabilities with market-leading next generation sequencing technology to better understand the genetics of infertility for future development of a diagnostic solution.”
Worldwide, around 70 to 80 million couples currently experience infertility, which causes significant depression, anxiety, and loss of work productivity. The ability to identify women who will experience trouble conceiving will allow for early intervention and personalized treatment planning that may result in fewer cycles to achieve a successful pregnancy.
“We look forward to this exciting and important work with Predictive Laboratories to better understand infertility in women,” said Yan Zhang, general manager, reproductive health at Thermo Fisher. “With the combination of our partner’s expertise and our advanced solutions for genetic analysis, we are committed to reducing the future financial and emotional burden couples face while undergoing fertility treatment.”
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. For more information, please visit www.thermofisher.com.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com; Predrx.com; Predictivebiotech.com; and Predictivelabs.com.
Mamie Reeder
Predictive Technology Group, Inc.
385-297-8067
mreeder@predtechgroup.com
ELEMENT GLOBAL, INC. (ELGL) TO MOVE CORPORATE OFFICES TO SOUTHERN CALIFORNIA
/in Element Global, Inc., Press Releases, Uncategorized /by Yes InternationalELEMENT GLOBAL, INC. (ELGL) TO MOVE CORPORATE OFFICES TO SOUTHERN CALIFORNIA
Virginia Beach, VA- June 6, 2019- Element Global, Inc. (ELGL: OTC) announces that it will move its corporate office from Virginia Beach, Virginia to Southern California, USA.
Management believes that its office move will better serve the interest of the Company’s operations with the intended move to California.
After reviewing several locations in Southern California, management expects to make a final decision with an announcement to follow on the new address.
As more information becomes available, the Company plans to update accordingly.
For further information about this release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, at 757-306-6090, yes@yesinternational.com and www.yesinternational.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.
ELEMENT GLOBAL, INC.’S (ELGL) CURRENT BOARD OF DIRECTORS MEET TO ADD BOARD AND OFFICER POSITIONS
/in Element Global, Inc., Press Releases /by Yes InternationalVirginia Beach, VA – June 5, 2019- Element Global, Inc. (ELGL: OTC) announces that its board of directors will meet the afternoon of June 6, 2019. The board will evaluate the credentials of several individual candidates for the possible board of directors and executive officer positions at the Company.
The “Exploratory Committee” will be attending this board meeting, providing their inputs and recommendations on the purposed candidates.
The Board expects to fill empty board seats and announce new executive officer positions.
Upon successful completion selection process of the candidates, and their acceptance into these corporate positions, the Company will then provide names and their business backgrounds at a time in the future.
Adding experts in their relevant fields remains an essential step in growing a Company to realize its full potential as a corporate entity.
Management continues on its fiduciary path with a primary objective of creating shareholder value.
As more information becomes available, the Company plans to update accordingly.
For further information about this release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, at 757-306-6090 and yes@yesinternational.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.
ELEMENT GLOBAL, INC. (ELGL) FORMS EXPLORATORY COMMITTEE
/in Element Global, Inc., Press Releases /by Yes InternationalVirginia Beach, VA- June 4, 2019- Element Global, Inc. (ELGL:OTC) announces that its Board of Directors and its management team formed a committee to explore numerous acquisition targets.
The Exploratory Committee’s (Committee) objectives are to look at the best possible outcome on potential acquisitions as it relates to being accretive to ELGL’s operational growth.
Using financial matrix and other available financial forecasting and methodologies, the Committee, in turn, determines the best possible outcome using such statistical information.
Upon completion of each reviewed potential acquisition, the Committee’s report(s), when presented to ELGL’s board, should provide information and other statistical evaluations to determine the feasibility of each potential purchase.
Management continues on its fiduciary path with a primary objective of creating shareholder value.
As more information becomes available, the Company plans to update accordingly.
For further information about this release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, at 757-306-6090 and yes@yesinternational.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.
Predictive Technology Group Names Industry Veteran Dr. Douglas Rabin Vice President of Medical Affairs, Women’s Health of Predictive Laboratories
/in Predictive Technology Group, Press Releases /by Yes InternationalAppointment expands Predictive Laboratories’ management team to support goal of bringing innovative molecular diagnostics to market
SALT LAKE CITY, June 04, 2019 (GLOBE NEWSWIRE) — Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, announces that Douglas S. Rabin, MD, has joined Predictive Laboratories as Vice President of Medical Affairs, Women’s Health. In this newly created position, he will provide critical medical affairs support for the women’s health clinical franchise. Dr. Rabin has more than 25 years of experience in women’s healthcare, including both clinical reproductive endocrinology, and obstetrics and gynecology.
Dr. Rabin previously served as Medical Director for Women’s Health at Quest Diagnostics, where he successfully completed a seminal paper in cervical cancer screening, initiated a trial in BRCA population testing and helped launch Quest’s non-invasive prenatal and Jewish genetic diagnostics. He also was instrumental in the expansion of the women’s health franchise at Quest through the acquisition of Reprosource, Inc. He previously was a National Health Service Corps (NHSC) physician, and a National Scholarship Awardee at the National Institutes of Health (NIH) and its gynecological consultant, as well as a consultant to multiple Big Four accounting firms. His clinical credentials include management of a successful in vitro fertilization (IVF) practice for more than 10 years and as a full-time obstetrician and gynecologist. In addition, Dr. Rabin served as the medical director for a pharmaceutical company addressing women’s health issues.
Dr. Rabin earned a bachelor’s degree in economics from Harvard College and a medical degree from the Temple University School of Medicine. He completed his Ob/Gyn training at the Hospital of the University of Pennsylvania and spent eight years at the NIH after completing a fellowship in endocrinology and infertility at Mt Sinai School of Medicine.
Dr. Rabin said, “I am extremely excited to join Predictive Technology Group. I view our diagnostics to identify patients with endometriosis as novel predictive approaches in managing fertility, pelvic pain and improving women’s lives.”
“We welcome Dr. Rabin to the Predictive team to support our goal of commercializing our innovative, genetic-based diagnostics that are initially focus on human infertility and women’s health,” said Bradley Robinson, CEO of Predictive Technology Group. “Dr. Rabin is highly accomplished in launching pharmaceutical and diagnostic products at Fortune 500 companies. His experience and commitment to delivering improved, more comprehensive healthcare to patients will be of tremendous assistance in supporting our mission of employing advanced molecular diagnostics to prevent or eliminate disease for generations to come.”
About Predictive Laboratories, Inc.
Predictive Laboratories owns significant next-generation sequencing and genotyping assets along with extensive protocols, quality and laboratory management systems and other resources required by a “high complexity” molecular diagnostic laboratory operating under the Clinical Laboratory Improvement Act (CLIA). Its novel test for women experiencing infertility, ARTGuide™, was launched in late 2018 to selected Beta launch centers. ARTGuide™ is a proprietary gene test panel for women experiencing infertility as a result of endometriosis and other health concerns. The test is expected to change the way that Advanced Reproductive Technologies (ART), such as IVF, are used to assist couples having difficulty conceiving a pregnancy.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, Predictive Diagnostics and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com; Predrx.com and Predictivebiotech.com.
Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.